Literature DB >> 3158276

Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.

H Goossens, P De Mol, H Coignau, J Levy, O Grados, G Ghysels, H Innocent, J P Butzler.   

Abstract

The in vitro activity of drugs currently used in the treatment of diarrhea against 595 enteropathogens from worldwide sources was compared with that of six newly developed antibiotics, ciprofloxacin; norfloxacin; ofloxacin; aztreonam; HR810, an expanded-spectrum cephalosporin; and RU28965, a new macrolide. In contrast with ampicillin and chloramphenicol, trimethoprim-sulfamethoxazole showed an excellent activity against all of the enteropathogens tested, except Campylobacter species. Ciprofloxacin had the highest activity, with an overall 90% MIC of less than or equal to 0.097 micrograms/ml, except for Campylobacter species (0.39 micrograms/ml). Unlike other cephalosporins, HR810 showed a satisfactory activity against Campylobacter species (90% MIC of 3.12 micrograms/ml). RU28965 was three times less active than erythromycin against Campylobacter species.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3158276      PMCID: PMC176282          DOI: 10.1128/AAC.27.3.388

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Possible field test for ST-producing Escherichia coli.

Authors:  P De Mol; F Van Wijnendaele; W Hemelhof; Y Corrazza
Journal:  Lancet       Date:  1983-03-05       Impact factor: 79.321

2.  Ceftazidime activity on multiresistant salmonella.

Authors:  H Goossens; R Vanhoof; O Grados; D Dekegel; J P Butzler
Journal:  Lancet       Date:  1982-10-02       Impact factor: 79.321

3.  In vitro comparison of the activity of RU 28965, a new macrolide, with that of erythromycin against aerobic and anaerobic bacteria.

Authors:  T Barlam; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

Review 4.  Antibiotic resistance of Salmonella in Europe and the United States.

Authors:  C E Cherubin
Journal:  Rev Infect Dis       Date:  1981 Nov-Dec

5.  In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs.

Authors:  R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

6.  Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens.

Authors:  L J Goodman; R M Fliegelman; G M Trenholme; R L Kaplan
Journal:  Antimicrob Agents Chemother       Date:  1984-04       Impact factor: 5.191

7.  Enteropathogenic agents in children with diarrhoea in rural Zaire.

Authors:  P de Mol; D Brasseur; W Hemelhof; T Kalala; J P Butzler; H L Vis
Journal:  Lancet       Date:  1983-03-05       Impact factor: 79.321

8.  Comparative in vitro activities of ten antimicrobial agents against bacterial enteropathogens.

Authors:  J R Carlson; S A Thornton; H L DuPont; A H West; J J Mathewson
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

9.  A new selective medium for the isolation of Campylobacter jejuni from human faeces.

Authors:  H Goossens; M De Boeck; J P Butzler
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

10.  In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.

Authors:  D L Shungu; E Weinberg; H H Gadebusch
Journal:  Antimicrob Agents Chemother       Date:  1983-01       Impact factor: 5.191

View more
  40 in total

1.  Characterization of high-level quinolone resistance in Campylobacter jejuni.

Authors:  T D Gootz; B A Martin
Journal:  Antimicrob Agents Chemother       Date:  1991-05       Impact factor: 5.191

Review 2.  Mechanisms of antibiotic resistance in Campylobacter species.

Authors:  D E Taylor; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

3.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

4.  Susceptibility of Campylobacter pyloridis to three macrolide antibiotics (erythromycin, roxithromycin [RU 28965], and CP 62,993) and rifampin.

Authors:  S Czinn; H Carr; S Aronoff
Journal:  Antimicrob Agents Chemother       Date:  1986-08       Impact factor: 5.191

Review 5.  Impact of the fluoroquinolones on gastrointestinal flora.

Authors:  V Korten; B E Murray
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 6.  Quinolones in Salmonella typhi infection.

Authors:  H L DuPont
Journal:  Drugs       Date:  1993       Impact factor: 9.546

7.  Characterization and description of "Campylobacter upsaliensis" isolated from human feces.

Authors:  H Goossens; B Pot; L Vlaes; C Van den Borre; R Van den Abbeele; C Van Naelten; J Levy; H Cogniau; P Marbehant; J Verhoef
Journal:  J Clin Microbiol       Date:  1990-05       Impact factor: 5.948

8.  Comparison of norfloxacin and nalidixic acid for treatment of dysentery caused by Shigella dysenteriae type 1 in adults.

Authors:  F Rogerie; D Ott; J Vandepitte; L Verbist; P Lemmens; I Habiyaremye
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

10.  Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.

Authors:  N Lachance; C Gaudreau; F Lamothe; F Turgeon
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.